PSMD3 exerts an oncogenic effect on chronic myeloid leukemia (CML) by stabilizing of nuclear factor-kappa B [16], therefore, PSMD3 is considered as a potential target for anti-cancer therapeutics in CML [17]. Here, PSMD3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.